Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Janssen (Details)

v3.24.1.u1
Licensing and Other Arrangements - Janssen (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Aug. 31, 2019
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2019
Dec. 31, 2024
Dec. 31, 2023
Licensing and other arrangements            
Revenue from contracts with customers   $ 1,000        
Janssen | License Agreement            
Licensing and other arrangements            
Cash payment received $ 2,500          
Maximum eligible milestone payments receivable per discovery product candidate $ 3,000          
Percentage of royalty on worldwide net sales of each product upon commercialization 0.75%          
Revenue from contracts with customers   0 $ 0 $ 2,500    
Contract assets   0       $ 0
Contract liabilities   $ 0       $ 0
Capitalized contract costs     $ 0   $ 0